Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

June 4th 2025

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma

June 4th 2025

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma

June 3rd 2025

Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

June 3rd 2025

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.

Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

June 3rd 2025

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

June 3rd 2025

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

D-VRd Retains Its Role as a Potential Standard of Care for Transplant-Ineligible Multiple Myeloma

June 2nd 2025

D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

Belantamab Mafodotin Triplet Improves PFS, Responses in R/R Myeloma With High-Risk Cytogenetics

June 2nd 2025

Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

Talquetamab Is Safe and Effective in R/R Multiple Myeloma

June 1st 2025

Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.

Cilta-Cel Boosts Survival Vs SOC Across Key Subgroups of R/R Multiple Myeloma

June 1st 2025

CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.

Dr Richardson on Optimal Treatment Strategies for 1q–Amplified Multiple Myeloma

May 30th 2025

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Dr Dholaria on the Mechanism of Action of P-BCMA-ALLO1 in Multiple Myeloma

May 30th 2025

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Dr Maroto-Martin on the Mechanism of MZB1-Targeted CAR T-Cell Therapy in Myeloma and Waldenström Macroglobulinemia

May 29th 2025

Elena Maroto-Martin, PhD, discusses the mechanism of action and therapeutic rationale for an MZB1-targeted CAR T-cell therapy in of multiple myeloma and Waldenström macroglobulinemia.

Elotuzumab Plus PVd Has Antitumor Activity in Heavily Pretreated R/R Myeloma

May 28th 2025

Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.

MZB1 TCR-Like CAR T-Cell Therapy Yields Antitumor Activity in Multiple Myeloma and Waldenström Macroglobulinemia

May 27th 2025

Elena Maroto-Martin, PhD, highlights the mechanism of action and efficacy of MZB1 TCR-like CAR T-cell therapy in multiple myeloma.

Talquetamab/Teclistamab Combo Yields Responses With Increased Infection Incidence in Triple Class–Exposed Myeloma

May 26th 2025

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25th 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Belantamab Mafodotin Combos Approach EU Approval for R/R Multiple Myeloma

May 23rd 2025

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of belantamab mafodotin (Blenrep) in adult patients with relapsed or refractory multiple myeloma.

Dr Fonseca on Selecting a Treatment in Relapsed/Refractory Myeloma

May 22nd 2025

Rafael Fonseca, MD, discusses factors for selecting a treatment in relapsed/refractory multiple myeloma.